🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Molecular tumor boards can enhance patient access to specialized oncology expertise, but logistical challenges persist in successfully enrolling patients onto molecular-driven clinical trials - a Duke Cancer experience. MDPI mdpi.com/1718-7729/31/1…

Congratulations to Diane Reidy-Lagunes, the incoming division chief of medical oncology Duke Department of Medicine! Welcome to the #DukeFamily.

Registration open. Hemophagocytic Lymphohistiocytosis (HLH) Across Pediatric Specialties: Spotlight on Immune Effector Cell HLH Like Syndrome pediatrics.duke.edu/blog/hemophago…

Launch: Duke Health and UNC Health, 2 of the world’s top academic health systems, unite to create a new children’s health system - NC's first freestanding hospital to care for kids. See more about the effort and timeline here: duke.is/2/jhf8 Duke Children's

🎉 Out now! 🎉 In this roundtable, Thomas LeBlanc, MD, MA, MHS, FAAHPM, FASCO, of Duke Cancer, Andrew Brunner, of MassGeneral News, and Jamie Koprivnikar, of JTCancerCenter, discuss findings from a Florida Cancer Specialists study on managing lower-risk #MDS. Watch here ➡️ buff.ly/3PREw7R

Congratulations to faculty member Sanghee Hong for her ASH Scholar Award! hematology.org/awards/award-r…

Metagenomics showed that cutaneous dysbiosis is present after allogeneic stem cell transplantation, but more research is needed to determine prognostic value. New research in Blood Advances by Dr. Nelson Chao, Dr. Keith Sullivan, Dr. Tony Sung, & Amy Bush.

This preclinical study in Leukemia Journal showed that ACOX1 inhibition may improve efficacy of proteasome inhibitors against multiple myeloma via reducing the degradation of very long chain fatty acids. Co-author Dr. Yubin Kang #MMsm nature.com/articles/s4137…

Today is #WorldCancerDay. On this day, I find myself reflecting upon the current state of #cancer care, and marveling at the remarkable advancements of the last decade, while recognizing the unmet needs that persist. Immune checkpoint inhibitors have revolutionized care and

ICYMI: Cristina Gasparetto, our Duke Cancer myeloma section lead, was the chief cyclist for the International Myeloma Foundation Iceland Cycling Expedition. This dedicated group of doctors, researchers, and patients biked across Iceland to raise money and awareness for #MultipleMyeloma and #MGUS. The

LABMT ASTCT The EBMT CIBMTR we’ll have many transplant groups & societies in the beautiful capital of Brazil-Brasilia-20-23 August 2025 (Wednesday-Saturday ). Come & join us🔝🔝🇧🇷🇧🇷Duke Children's & Duke Hematologic Malignancies & Cellular Therapy will be represented by Kris Mahadeo & Dr Nelson Chao ❤️❤️🔝🔝SBTMO

Duke Children's Dr Joanne Kurtzberg Shaikha Alqahtani MD Dr Fabiana Cacace Duke Hematologic Malignancies & Cellular Therapy Dr Keith Sullivan & Dr Nelson Chao ( ASTCT 6th international symposium & ASTCT international council ). Some of the amazing work presented by Duke university at #Tandem25 meeting! 🔝🔝❤️❤️Kris Mahadeo

Harry Erba Duke Hematologic Malignancies & Cellular Therapy with a fantastic talk on targeted therapies in IDH-mutated MDS & AML at the 2nd Annual Chris Perri Leukemia Symposium UNC Lineberger

An excellent commentary by Sanghee Hong, Vice Chief of Equity Diversity and Inclusion, and Mitch Horwitz, Vice Chief of Transplantation, in NEJM Evidence on the pressing need to improve access to sickle cell disease therapies. evidence.nejm.org/doi/full/10.10…

Proud to be part of an amazing Duke Team that makes this possible for our patients. #wral LucStrong Foundation #sicklecell #genetherapy Carmem Bonfim Shaikha Alqahtani MD

Ruxolitinib Therapy for cGVHD: Insights on Patient and Safety Monitoring | Duke Hematologic Malignancies & Cellular Therapy hubs.li/Q03j6WL80

Panelists discuss how the decision to initiate cytoreductive therapy in polycythemia vera is driven by high-risk features such as age over 60 and thrombotic history. Duke Hematologic Malignancies & Cellular Therapy IU Simon Comprehensive Cancer Center Andrew Kuykendall MD Moffitt Cancer Center hubs.li/Q03ldKw40

Congratulations to our faculty, Sanghee Hong, on her #ASH Scholar early career award this year for survivorship research! medicine.duke.edu/news/dr-sanghe…